Anti-HIV drug Lenacapavir shows 100% efficacy, no safety concerns in women: Study – Firstpost

  • Post category:Latest News
  • Post comments:0 Comments
  • Post last modified:November 5, 2024

Lenacapavir, injectable twice a year, is developed by the US-based biopharmaceutical company Gilead Sciences, Inc. as a pre-exposure prophylaxis (PrEP) drug. These drugs prevent the spread of infection in people…

Continue ReadingAnti-HIV drug Lenacapavir shows 100% efficacy, no safety concerns in women: Study – Firstpost